(3S)-3-amino-2-methyl-pentan-2-ol | 74608-29-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S)-3-amino-2-methyl-pentan-2-ol
• 英文别名: (S)-3-Amino-2-methyl-2-pentanol；(3S)-3-amino-2-methylpentan-2-ol
• CAS: 74608-29-0
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: RJQQAAMUEHNMSQ-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-benzyl-2-fluoro-9-isopropyl-purin-6-amine 、 (3S)-3-amino-2-methyl-pentan-2-ol 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 正丁醇 为溶剂， 反应 72.0h， 生成 6-benzylamino-2-[(1S)-1-ethyl-2-hydroxy-2-methylpropylamino]-9-isopropylpurine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051
• 作为产物：
  描述：

  (3R)-2-methyl-3-(trityl-amino)-pentan-2-ol 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (3S)-3-amino-2-methyl-pentan-2-ol
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051

文献信息

• [EN] FACTOR XIIa INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIIA
  申请人：MERCK SHARP & DOHME

  公开号：WO2018093695A1

  公开（公告）日：2018-05-24

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

  本发明提供了一种化合物(I)及包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。这些化合物是选择性凝血因子XIIa抑制剂。
• [EN] SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS<br/>[FR] BICYCLO-COMPOSÉS DE TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2017000277A1

  公开（公告）日：2017-01-05

  The present invention is directed to substituted triazolo bicycliccompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及一种用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的式（I）的取代三唑杂双环化合物，该化合物可用作治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的化合物的用途。
• Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate
  作者：Yong-Kang Zhang、Jacob J. Plattner、Eric E. Easom、Robert T. Jacobs、Denghui Guo、Yvonne R. Freund、Pamela Berry、Vic Ciaravino、John C. L. Erve、Philip J. Rosenthal、Brice Campo、Francisco-Javier Gamo、Laura M. Sanz、Jianxin Cao

  DOI：10.1021/acs.jmedchem.7b00621

  日期：2017.7.13

  resistant to chloroquine and pyrimethamine. The rapid parasite in vitro reduction and in vivo parasite clearance profile of 46 were similar to those of artemisinin and chloroquine, two rapid-acting antimalarials. It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg. The combined properties of this novel benzoxaborole

  为了确定具有令人满意的抗疟活性，理化性质，药代动力学特征，体内功效和安全性特征的分子，对羧酰胺基吡嗪酰氧基苯并氧杂硼酸酯进行了研究。这项优化工作发现了46个，满足了我们的目标候选人档案。化合物46对培养的恶性疟原虫具有优异的活性，并且在感染的小鼠体内对恶性疟原虫和伯氏疟原虫具有体内活性。它在小鼠，大鼠和狗中表现出良好的PK特性。它对其他11种恶性疟原虫非常活跃菌株，大多数对氯喹和乙胺嘧啶有抗性。46种体外快速寄生虫减少和体内寄生虫清除率特征与青蒿素和氯喹（两种速效抗疟药）相似。当口服剂量高达2000 mg / kg时，在Ames分析，体外微核分析和体内大鼠微核分析中均无遗传毒性。这种新颖的苯并氧杂硼酸酯的综合性能支持其向临床前发展的进程。
• [EN] 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE PURINE 2,6,9-SUBSTITUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFERANTES
  申请人：CYCLACEL LTD

  公开号：WO2003002565A1

  公开（公告）日：2003-01-09

  The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein R2 is 3-hydroxypiperidin-1-yl, or NHCH(R4)CH(R3) OH, wherein R3 is hydrogen or methyl and R4 is methyl, ethyl or isopropyl; R6 is 3-nitrophenylarnino, 3,4-dimethoxybenzylarnino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino; R9 is isopropyl or cyclopentanyl. In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and/or viral disorders.

  本发明涉及公式I的化合物或其药学上可接受的盐，其中R2为3-羟基哌啶-1-基或NHCH（R4）CH（R3）OH，其中R3为氢或甲基，R4为甲基、乙基或异丙基；R6为3-硝基苯胺基、3,4-二甲氧基苄胺基、吡啶-2-基甲基氨基、吡啶-4-基甲基氨基或茚-5-基氨基；R9为异丙基或环戊基。在另一个方面，本发明涉及包含所述化合物的药物组合物，以及它们在治疗抗增殖性疾病和/或病毒性疾病中的应用。
• New purine derivatives
  申请人：Fischer Martin Peter

  公开号：US20050256142A1

  公开（公告）日：2005-11-17

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R 1 and R 2 is methyl, ethyl or isopropyl, and the other is H; R 3 and R 4 are each independently H, branched or unbranched C 1 -C 6 alkyl, or aryl, and wherein at least one of R 3 and R 4 is other than H; R 5 is a branched or unbranched C 1 -C 5 alkyl group or a C 1 -C 6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R 6 , R 7 , R 8 and R 9 are each independently H, halogen, NO 2 , OH, OMe, CN, NH 2 , COOH, CONH 2 , or SO 2 NH 2 . A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基，或芳基，其中至少一个是非氢基；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团可以选择性地被一个或多个羟基取代；R6、R7、R8和R9各自独立地是氢、卤素、NO2、羟基、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包括公式1化合物的药物组合物，以及使用该化合物治疗增生性疾病、病毒性疾病、中枢神经系统疾病、糖尿病、中风、脱发或神经退行性疾病的用途。